A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTryfonidis, Konstantinos
dc.contributor.authorBasaran, Gul
dc.contributor.authorBogaerts, Jan
dc.contributor.authorDebled, Marc
dc.contributor.authorDirix, Luc
dc.contributor.authorThery, Jean\\-Christophe
dc.contributor.authorTjan\\-Heijnen, Vivianne C. G.
dc.contributor.authorVan den Weyngaert, Danielle
dc.contributor.authorCufer, Tanja
dc.contributor.authorPiccart, Martine
dc.contributor.authorCameron, David
dc.contributor.authorEORTC\\-Breast Canc Grp
dc.date.accessioned2025-10-16T15:29:54Z
dc.date.issued2016
dc.identifier.doi10.1016/j.ejca.2015.10.012
dc.identifier.otherWOS:000368789100016
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8842
dc.publisherELSEVIER SCI LTD
dc.sourceEUROPEAN JOURNAL OF CANCER
dc.subjectAnastrozole
dc.subjectGefitinib
dc.subjectMetastatic breast cancer
dc.subjectEndocrine resistance
dc.titleA European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS